These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37531922)

  • 1. Lipophilic modification of salirasib modulates the antiproliferative and antimigratory activity.
    Ballari MS; O J Porta E; Zalazar EA; Etichetti CMB; Padrón JM; Girardini JE; Labadie GR
    Bioorg Med Chem; 2023 Sep; 92():117417. PubMed ID: 37531922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
    Charette N; De Saeger C; Lannoy V; Horsmans Y; Leclercq I; Stärkel P
    Mol Cancer; 2010 Sep; 9():256. PubMed ID: 20860815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
    Zundelevich A; Elad-Sfadia G; Haklai R; Kloog Y
    Mol Cancer Ther; 2007 Jun; 6(6):1765-73. PubMed ID: 17541036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
    Wolfson E; Schmukler E; Schokoroy ST; Kloog Y; Pinkas-Kramarski R
    Biol Cell; 2015 May; 107(5):130-43. PubMed ID: 25735913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
    Sugita S; Enokida H; Yoshino H; Miyamoto K; Yonemori M; Sakaguchi T; Osako Y; Nakagawa M
    Int J Oncol; 2018 Aug; 53(2):725-736. PubMed ID: 29901113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
    Rotblat B; Ehrlich M; Haklai R; Kloog Y
    Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
    Haklai R; Elad-Sfadia G; Egozi Y; Kloog Y
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):89-96. PubMed ID: 17909812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
    Makovski V; Haklai R; Kloog Y
    Int J Cancer; 2012 Mar; 130(6):1420-9. PubMed ID: 21500191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
    Blum R; Elkon R; Yaari S; Zundelevich A; Jacob-Hirsch J; Rechavi G; Shamir R; Kloog Y
    Cancer Res; 2007 Apr; 67(7):3320-8. PubMed ID: 17409441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
    Laheru D; Shah P; Rajeshkumar NV; McAllister F; Taylor G; Goldsweig H; Le DT; Donehower R; Jimeno A; Linden S; Zhao M; Song D; Rudek MA; Hidalgo M
    Invest New Drugs; 2012 Dec; 30(6):2391-9. PubMed ID: 22547163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
    Badar T; Cortes JE; Ravandi F; O'Brien S; Verstovsek S; Garcia-Manero G; Kantarjian H; Borthakur G
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):433-438.e2. PubMed ID: 25795639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
    Aizman E; Mor A; Levy A; George J; Kloog Y
    Oncotarget; 2012 Feb; 3(2):144-57. PubMed ID: 22323550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stringent structural requirements for anti-Ras activity of S-prenyl analogues.
    Aharonson Z; Gana-Weisz M; Varsano T; Haklai R; Marciano D; Kloog Y
    Biochim Biophys Acta; 1998 Feb; 1406(1):40-50. PubMed ID: 9545527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.
    Charette N; De Saeger C; Horsmans Y; Leclercq I; Stärkel P
    Cell Death Dis; 2013 Jan; 4(1):e471. PubMed ID: 23348585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
    Yaari-Stark S; Shaked M; Nevo-Caspi Y; Jacob-Hircsh J; Shamir R; Rechavi G; Kloog Y
    Int J Cancer; 2010 May; 126(10):2268-81. PubMed ID: 19998334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
    Zhao Y; Fan D; Ru B; Cheng KW; Hu S; Zhang J; Li ET; Wang M
    Eur J Cancer; 2016 Nov; 68():38-50. PubMed ID: 27710830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras inhibition enhances autophagy, which partially protects cells from death.
    Schmukler E; Grinboim E; Schokoroy S; Amir A; Wolfson E; Kloog Y; Pinkas-Kramarski R
    Oncotarget; 2013 Jan; 4(1):145-55. PubMed ID: 23370967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
    Goldberg L; Haklai R; Bauer V; Heiss A; Kloog Y
    J Med Chem; 2009 Jan; 52(1):197-205. PubMed ID: 19072665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
    Barkan B; Kloog Y; Ehrlich M
    Mol Cancer Ther; 2011 Aug; 10(8):1317-26. PubMed ID: 21632464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
    Gana-Weisz M; Halaschek-Wiener J; Jansen B; Elad G; Haklai R; Kloog Y
    Clin Cancer Res; 2002 Feb; 8(2):555-65. PubMed ID: 11839677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.